Synonym
Sultosilic acid, piperazine salt; Mimedran; A585; A-585; A 585; piperazine-sultosylate
IUPAC/Chemical Name
2-Hydroxy-5-(((p-tolyl)sulphonyl)oxy)benzenesulphonic acid, compound with piperazine (1:1)
InChi Key
HGAVKWUHBLHFNP-UHFFFAOYSA-N
InChi Code
InChI=1S/C13H12O7S2.C4H10N2/c1-9-2-5-11(6-3-9)22(18,19)20-10-4-7-12(14)13(8-10)21(15,16)17;1-2-6-4-3-5-1/h2-8,14H,1H3,(H,15,16,17);5-6H,1-4H2
SMILES Code
O=S(C1=CC(OS(=O)(C2=CC=C(C)C=C2)=O)=CC=C1O)(O)=O.N3CCNCC3
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
430.49
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Vinazzer H, Farine JC. Double-blind cross-over study of the effect of sultosilic acid piperazine salt (A-585) and bezafibrate in primary hyperlipoproteinemia. Atherosclerosis. 1983 Nov;49(2):109-18. PubMed PMID: 6686778.
2: Vinazzer H. [Comparison of the antilipemic effect of bezafibrate with that of piperazine-sultosilate (A 585). A crossed double-blind study]. Wien Klin Wochenschr. 1984 Dec 21;96(24):889-93. German. PubMed PMID: 6152088.
3: Rodríguez L, Demestre I, Sagarra R, Laporte J, Esteve A. [Toxicologic study of piperazine sultosylate (A-585)]. Arch Farmacol Toxicol. 1979 Dec;5(3):281-3.Spanish. PubMed PMID: 546355.
4: Casellas Bernat A, Ribas Grau M, Casellas Bernat G, Riera de Barcia L, Alou Llado M, Solivellas Antich S. [Clinical effectiveness of piperazine sultosylate in the hyperlipidemias]. Rev Clin Esp. 1981 Apr 25;161(1):5-8. Spanish. PubMed PMID: 7255818.
5: Rodríguez L, Roser R, Palacios G, Sagarra R, Esteve A. [Hypolipemic activity of piperazine sultosylate (A-585) in the rat and chicken]. Arch Farmacol Toxicol. 1979 Dec;5(3):272-4. Spanish. PubMed PMID: 546353.
6: Rodríguez L, Parés S, Laporte J, Roser R, Esteve J. [Effect of piperazine sultosylate (A-585) on hypertriglyceridemia induced by ethanol in man]. Arch Farmacol Toxicol. 1979 Dec;5(3):235-7. Spanish. PubMed PMID: 546346.
7: Masana L, Villoria J, Sust M, Ros E, Plana N, Pérez-Jiménez F, Franco M, Oliván JJ, Pintó X, Videla S. Treatment of type IIb familial combined hyperlipidemia with the combination pravastatin-piperazine sultosilate. Eur J Pharmacol. 2004 Aug 2;496(1-3):205-12. PubMed PMID: 15288592.
